Venture&Growth Archives - Gilde Healthcare

Neuigkeiten & Einblicke
Venture&Growth

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant Cell Tumour TANGENT Study Underway with First Patients Dosed SynOx Therapeutics Limited (“SynOx”), a late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related...
30. Oktober 2024

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

test Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova Partners, Forbion, and British Patient Capital with founding investor Syncona Purespring Therapeutics, a pioneering gene therapy company focused on transforming […]

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

test ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS Adcendo ApS […]

Gilde Healthcare company Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug (ADC) conjugate program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will continue in role of Chief Scientific Officer and as a member of...

Gilde Healthcare company Spire Health merges with Wellinks to form Industry Leader in Predictive Patient Care for Cardiopulmonary Health

Wellinks, the industry leader in virtual-led cardiopulmonary care, announced today it has merged with Spire Health in a non-cash transaction. The transaction merges Spire’s novel patient monitoring technology with Wellinks highly specialized virtual-led cardiopulmonary care model creating a first of its kind fully integrated Predictive Patient Care company....

Gilde Healthcare company Big Health receives US FDA Clearance for DaylightRx

First FDA cleared non-drug treatment for generalized anxiety disorder. Clearance is the second FDA-clearance for Big Health. Big Health, a leading developer of digital mental health treatments, has been granted clearance by the U.S. Food and Drug Administration (FDA) for its digital therapeutic, DaylightRx. DaylightRx is a...

Gilde Healthcare company Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline Appointment follows achievement of three key milestones for Amphista in 2024 which demonstrated: in vivo efficacy, ability to target and degrade...

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international biotech investors Gilde Healthcare, Canaan Partners, Bioqube Ventures, Omega Funds and Forbion...

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone. Volta Medical, a pioneering health-tech company developing AI based solutions to assist...
Loading...
These were all messages
871ebbf0b6